Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr:179:106336.
doi: 10.1016/j.rmed.2021.106336. Epub 2021 Feb 16.

Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and future

Affiliations
Free article
Review

Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and future

Beate Stubbe et al. Respir Med. 2021 Apr.
Free article

Abstract

Therapy with intravenous prostacyclin analogues in patients with pulmonary arterial hypertension (PAH) has been established for decades and is an integral component of the current guidelines for the treatment of pulmonary hypertension. Initially, these drugs were infused by external pump systems via tunnelled right atrial catheters with the need for cooling and frequent exchange of drug reservoirs. Associated complications included, among others, catheter-related infections. More recently, fully implantable pump systems have been developed with drug reservoirs that are filled transcutaneously, allowing intervals between refills of several weeks. This technique results in a low rate of infections. Epoprostenol, iloprost and treprostinil have all been used intravenously in PAH, but titration, dosing and dose escalation in long-term therapy are not standardized. Intravenous prostacyclin analogues are still under-used, despite available data suggesting that early and broad application of these therapies as part of risk-oriented, guideline-directed combination therapy for patients with PAH may lead to a survival benefit. This review provides a detailed overview of the drugs, infusion systems and dosing strategies used for intravenous therapy in patients with PAH.

Keywords: Epoprostenol; Iloprost; Implantable drug pump; Prostacyclin; Pulmonary arterial hypertension; Treprostinil.

PubMed Disclaimer

MeSH terms

LinkOut - more resources